The immune receptors TLR4 and SLAMF1 regulate TNF release by human metapneumovirus in human macrophages

Katja Sæterhaug Bye1, Kristin Rian1, Liv Ryan1

  • 1Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.

Frontiers in Immunology
|December 5, 2025
PubMed
Abstract

Insights

Human metapneumovirus (HMPV) triggers inflammation via Toll-like receptor 4 (TLR4) and signaling lymphocytic activation molecule family 1 (SLAMF1) pathways. Targeting these receptors may limit severe HMPV-induced tumor necrosis factor (TNF) responses.

Area of Science:

  • Immunology
  • Virology
  • Cell Biology

Background:

  • Human metapneumovirus (HMPV) causes severe respiratory illness, particularly in vulnerable populations.
  • Excessive tumor necrosis factor (TNF) production correlates with disease severity in HMPV infections.
  • The roles of Toll-like receptor 4 (TLR4) and signaling lymphocytic activation molecule family 1 (SLAMF1) in HMPV-induced cytokine responses remain unclear.

Purpose of the Study:

  • To investigate the regulatory mechanisms of HMPV-induced TNF and interferon-beta (IFN-β) expression.
  • To determine the involvement of TLR4 and SLAMF1 in HMPV-stimulated cytokine production and p38 MAPK activation.

Main Methods:

  • Kinetics of TNF and IFNB1 expression were analyzed in human monocyte-derived macrophages (MDMs) and THP-1 cells.
  • TLR4 and SLAMF1 were manipulated (overexpression, knockout, silencing) to assess their impact on cytokine and p38 MAPK signaling.
  • Pharmacological inhibition of p38 MAPK was used to confirm its role in cytokine induction.

Main Results:

  • TLR4 knockout reduced HMPV-induced TNF but not IFN-β.
  • SLAMF1 silencing decreased both TNF and IFN-β expression.
  • Overexpression of TLR4 or SLAMF1 enhanced p38 MAPK activation and TNF secretion, while silencing had the opposite effect.
  • p38 MAPK inhibition reduced both TNF and IFN-β production.

Conclusions:

  • TLR4 and SLAMF1 are key regulators of early HMPV-induced inflammation through the p38 MAPK pathway.
  • SLAMF1 also influences IFN-β responses and potentially viral replication.
  • Targeting SLAMF1-TLR4 signaling presents a potential therapeutic strategy for HMPV-associated pathology.